Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sunday share tips: Futura Medical, Serco

(Sharecast News) - The Sunday Times's Lucy Tobin told readers that shares of Futura Medical were worth a punt, even if there were no guarantees of a happy ending.

Although the company had just 14 staff and directors, it had a new product that worked, Eroxon, a gel for those suffering from erectile dysfunction, which did not require a prescription in order to be sold.

Given that the market for ED was expected to surpass $6bn in value by 2032, the business's future looked appealing.

And unlike rival products Viagra and Cialis, both of which required a prescription, Eroxon took just 10 minutes to work, not half an hour.

The company was expecting approval for Eroxon in Saudi Arabia in September and was working on having a US partner for commercialisation which would likely a surge in the share price.

"There are no guarantees of a happy ending, but it's a worthy punt. Buy."

The Financial Mail on Sunday's told readers to 'buy' shares of Serco, although it conceded that risks were not absent.

The outsourcer was well-placed to benefit form government outlays on immigration and defence in many regions of the world, the tipster argued.

On the flip-side, there were multiple potential risks.

For starters, making up the loss of Covid-related work "wasn't always easy".

Furthermore, the possibility existed that it might lose the Australian immigration contract that was up for renewal in 2023.

Serco also had a tendency to work in "high-profile" and "controversial" areas, including on immigration which in the past had led to scandal and had an extremely negative impact on its share prices.

"There's no suggestion that the current management is likely to lead the company into any problems like this though, since former chief executive Rupert Soames is credited with shaking out any problems at the business, leaving it in stronger shape.

"At 156p, the shares are a buy."

Share this article

Related Sharecast Articles

Wednesday newspaper round-up: Post Office, Spirit AeroSystems, Flutter
(Sharecast News) - The Post Office is expected to announce the closure of dozens of branches and cut up to 1,000 head office jobs as it seeks to reduce costs to secure its financial future. There are about 11,500 Post Office branches across the UK, of which 115 are wholly centrally owned. The rest are operated by independent post office operators under contract and partners such as WH Smith and Tesco. - Guardian
Tuesday newspaper round-up: Bluesky, British Steel, FRC
(Sharecast News) - Social media platform Bluesky has picked up more than 700,000 new users in the week since the US election, as users seek to escape misinformation and offensive posts on X. The influx, largely from North America and the UK, has helped Bluesky reach 14.5 million users worldwide, up from 9 million in September, the company said. - Guardian
Monday newspaper round-up: Hospitality, wind generation, Vertical Aerospace
(Sharecast News) - Great Britain "lags behind" Europe on measures to restrict betting adverts, according to a report released days after official data showed a sharp increase in the number of children with a gambling problem. Restrictions on ads by bookmakers and casinos are increasingly becoming "the norm" across Europe in response to public health concerns, according to a report commissioned by GambleAware, the UK's leading gambling charity. - Guardian
Friday newspaper round-up: AI, Bentley, News Corp
(Sharecast News) - Dozens of health and children's groups have urged ministers to tackle obesity by imposing taxes on foods containing too much salt or sugar. New levies based on the sugar tax on soft drinks would make it easier for consumers to eat more healthily by forcing food manufacturers to reformulate their products, they claim. - Guardian

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.